Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review

Medical Hypotheses

Volumn 79, Issue 1, 2012, Pages 38-42

  Fond, G ^a,b,c   Macgregor, A ^a,b,c   Attal, J ^b,c   Larue, A ^a,b,c   Brittner, M ^b,c   Ducasse, D ^b,c   Capdevielle, D ^a,b,c  

^a UNIV MONTPELLIER   (France)

^b INSERM U1061   (France)

^c Montpellier 1 University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; COLON CANCER; DRUG CARCINOGENICITY; DRUG CYTOTOXICITY; GENOTOXICITY; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; IN VITRO STUDY; LEUKEMIA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RECTUM CANCER; RISK ASSESSMENT; RISK REDUCTION; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MICE; NEOPLASMS; RISK FACTORS;

ANIMALIA; RODENTIA;

EID: 84861461330     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.03.026     Document Type: Article

References (49)

1. Barnett A.H., Mackin P., Chaudhry I., Farooqi A., Gadsby R., Heald A., et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007, 21:357-373.
2. Osborn D.P., Levy G., Nazareth I., Petersen I., Islam A., King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007, 64:242-249.
3. Smith S., Yeomans D., Bushe C.J., Eriksson C., Harrison T., Holmes R., et al. A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2years. Eur Psychiatry 2007, 22:413-418.
4. Barak Y., Achiron A., Mandel M., Mirecki I., Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer 2005, 104:2817-2821.
5. Bushe C.J., Taylor M., Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2009, 24:17-25.
6. Chou F.H., Tsai K.Y., Su C.Y., Lee C.C. The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res 2010, 129:97-103.
7. Cohen M., Dembling B., Schorling J. The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res 2002, 57:139-146.
8. Dalton S.O., Laursen T.M., Mellemkjaer L., Johansen C., Mortensen P.B. Risk for cancer in parents of patients with schizophrenia. Am J Psychiatry 2004, 161:903-908.
9. Dalton S.O., Laursen T.M., Mortensen P.B., Johansen C. Major life event - diagnosis of schizophrenia in offspring and risk for cancer. Br J Cancer 2004, 90:1364-1366.
10. Dalton S.O., Schuz J., Engholm G., Johansen C., Kjaer S.K., Steding-Jessen M., et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: summary of findings. Eur J Cancer 2008, 44:2074-2085.
11. Damjanovic A., Ivkovic M., Jasovic-Gasic M., Paunovic V. Comorbidity of schizophrenia and cancer: clinical recommendations for treatment. Psychiatr Danub 2006, 18:55-60.
12. du Pan R.M., Muller C. Cancer mortality in patients of psychiatric hospitals. Schweiz Med Wochenschr 1977, 107:597-604.
13. Goldacre M.J., Kurina L.M., Wotton C.J., Yeates D., Seagroat V. Schizophrenia and cancer: an epidemiological study. Br J Psychiatry 2005, 187:334-338.
14. Grinshpoon A., Barchana M., Ponizovsky A., Lipshitz I., Nahon D., Tal O., et al. Cancer in schizophrenia: is the risk higher or lower?. Schizophr Res 2005, 73:333-341.
15. Hodgson R., Wildgust H.J., Bushe C.J. Cancer and schizophrenia: is there a paradox?. J Psychopharmacol 2010, 24:51-60.
16. Lehman A.F., Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B., Goldberg R., et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations. Schizophr Bull 2003, 30(2004):193-217.
17. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007, 116:317-333.
18. Levav I., Kohn R., Barchana M., Lipshitz I., Pugachova I., Weizman A., et al. The risk for cancer among patients with schizoaffective disorders. J Affect Disord 2009, 114:316-320.
19. Lichtermann D. Cancer risk in parents of patients with schizophrenia. Am J Psychiatry 2005, 162:1024. [Author reply 1024-1026].
20. Mortensen P.B. Relation between schizophrenia and cancer. Ugeskr Laeger 1987, 149:2999-3002.
21. Mortensen P.B. Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients. Acta Psychiatr Scand 1987, 75:585-590.
22. Mortensen P.B. Diagnosis of cancer and autopsy rate in schizophrenic patients. Ugeskr Laeger 1987, 149:1973-1975.
23. Mortensen P.B. Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients. Acta Psychiatr Scand 1992, 85:390-393.
24. Mortensen P.B. The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res 1994, 12:185-194.
25. Mortensen P.B., Juel K. Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 1990, 81:372-377.
26. Oksbjerg Dalton S., Munk Laursen T., Mellemkjaer L., Johansen C., Mortensen P.B. Schizophrenia and the risk for breast cancer. Schizophr Res 2003, 62:89-92.
27. Torrey E.F. Prostate cancer and schizophrenia. Urology 2006, 68:1280-1283.
28. U.S. Department of Health and Human Services,MA, July 1997.
29. FDA, http://www.fda.gov.cder.
30. Thomson PDR. Physicians' desk reference. 59th ed. Thomson Healthcare; 2005.
31. Nordenberg J., Fenig E., Landau M., Weizman R., Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol 1999, 58:1229-1236.
32. Brambilla G., Mattioli F., Martelli A. Genotoxic and carcinogenic effects of antipsychotics and antidepressants. Toxicology 2009, 261:77-88.
33. Drori S., Eytan G.D., Assaraf Y.G. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995, 228:1020-1029.
34. Kataoka Y., Ishikawa M., Miura M., Takeshita M., Fujita R., Furusawa S., et al. Reversal of vinblastine resistance in human leukemic cells by haloperidol and dihydrohaloperidol. Biol Pharm Bull 2001, 24:612-617.
35. Wiklund E.D., Catts V.S., Catts S.V., Ng T.F., Whitaker N.J., Brown A.J., et al. Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. Int J Cancer 2010, 126:28-40.
36. Zhelev Z., Ohba H., Bakalova R., Hadjimitova V., Ishikawa M., Shinohara Y., et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes phenothiazines and leukemia. Cancer Chemother Pharmacol 2004, 53:267-275.
37. Argyriou A.A., Antonacopoulou A., Iconomou G., Kalofonos H.P. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 2009, 69:199-210.
38. Gil-Ad I., Shtaif B., Levkovitz Y., Dayag M., Zeldich E., Weizman A. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. J Mol Neurosci 2004, 22:189-198.
39. Strobl J.S., Melkoumian Z., Peterson V.A., Hylton H. The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide. Breast Cancer Res Treat 1998, 51:83-95.
40. Hermes G., Ajioka J.W., Kelly K.A., Mui E., Roberts F., Kasza K., et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflamm 2008, 5:48.
41. Donohue J.M., Frank R.G. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders. Psychiatr Serv 2007, 58:1285-1291.
42. Hay M.P., Lee H.H., Wilson W.R., Roberts P.B., Denny W.A. Hypoxia-selective antitumor agents. 10. bis(Nitroimidazoles) and related bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility. J Med Chem 1995, 38:1928-1941.
43. McCreadie R.G. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 2002, 181:321-325.
44. Seeman M.V. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull 2009, 35:937-948.
45. Carlsen K., Oksbjerg Dalton S., Frederiksen K., Diderichsen F., Johansen C. Cancer and the risk for taking early retirement pension: a Danish cohort study. Scand J Public Health 2008, 36:117-125.
46. Gulbinat W., Dupont A., Jablensky A., Jensen O.M., Marsella A., Nakane Y., et al. Cancer incidence of schizophrenic patients. Results of record linkage studies in three countries. Br J Psychiatry Suppl 1992, 75-83.
47. Dalton S.O., Johansen C., Poulsen A.H., Norgaard M., Sorensen H.T., McLaughlin J.K., et al. Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer 2006, 95:934-939.
48. Harlow B.L., Cramer D.W., Baron J.A., Titus-Ernstoff L., Greenberg E.R. Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1998, 7:697-702.
49. Nielsen J., Boysen A. Clozapine treatment associated with increased risk of acute myeloid leukemia (AML). Schizophr Res 2010, 123:270-272.